Entera Bio (ENTX) Cash from Investing Activities (2021 - 2026)
Entera Bio's (ENTX) quarterly Cash from Investing Activities came in at -$27000.0 in Q4 2025, down 800.0% YoY from $3857.1 in Q4 2024, and up 37.21% on a QoQ basis from -$43000.0 in Q3 2025.
Entera Bio (ENTX) Cash from Investing Activities (2021 - 2026) Analysis & Trends
Entera Bio (ENTX) has 5 years of Cash from Investing Activities data on file, last reported at -$27000.0 in Q4 2025.
- Quarterly Cash from Investing Activities fell 800.0% year-over-year to -$27000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was -$99000.0 (down 800.0% YoY) and the FY2025 annual result came in at -$107000.0, down 3466.67% from the prior year.
- Cash from Investing Activities grew to -$27000.0 in Q4 2025, from -$43000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of -$1000.0 in Q2 2023 to a low of -$57000.0 in Q3 2022.
- A 5-year average of -$17571.4 and a median of -$10500.0 in 2021 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities jumped 94.74% — and 2025, when it plunged 800.0%.
- Tracing ENTX's Cash from Investing Activities over 5 years: stood at -$10000.0 in 2021, then surged by 70.0% to -$3000.0 in 2022, then slumped by 66.67% to -$5000.0 in 2023, then jumped by 40.0% to -$3000.0 in 2024, then sank by 800.0% to -$27000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$27000.0 (Q4 2025), -$43000.0 (Q3 2025), and -$29000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Entera Bio | 161.44 Mn | 150.13 Mn | - | -3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3,000.00 |
| Jun 30, 2026 | -3,000.00 |
| Dec 31, 2025 | -27,000.00 |
| Dec 31, 2025 | -27,000.00 |
| Sep 30, 2025 | -43,000.00 |
| Sep 30, 2025 | -43,000.00 |
| Jun 30, 2025 | -29,000.00 |
| Jun 30, 2025 | -29,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Mar 31, 2025 | -8,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2024 | -3,000.00 |
| Dec 31, 2023 | -5,000.00 |
| Dec 31, 2023 | -5,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Jun 30, 2023 | -1,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Dec 31, 2022 | -3,000.00 |
| Dec 31, 2022 | -3,000.00 |